Evidence guide · UK
NAD+ and nicotinamide riboside in heart failure: what the first meta-analysis of the trials found
A 17 November 2026 meta-analysis of four randomised trials (387 patients) found no significant benefit from intravenous NAD+ or oral nicotinamide riboside in heart failure, and a small creatinine rise. The trials, the limits and what it means for NAD+ products.
Review type: research summary. This page summarises published research and product labels, cited below.
NAD+ is a coenzyme that cells use to make energy. The authors of the meta-analysis below state that mitochondrial dysfunction and NAD+ depletion contribute to heart failure, and that trials of NAD+ and nicotinamide riboside (NR) have been inconsistent. On 17 November 2026 the European Journal of Clinical Pharmacology published the first meta-analysis of randomised trials of NAD+ or NR in adults with heart failure.
Short answer: across four small trials with 387 patients, intravenous NAD+ or oral NR, added to standard heart-failure medicines, did not significantly reduce hospital admissions for heart failure or deaths, and did not significantly improve heart pumping function or a key blood marker of heart strain. Serum creatinine, a kidney blood marker, rose slightly. The authors call for larger and longer trials. Nothing here supports using NAD+ products to manage heart failure, and anyone with heart failure should not add one without asking their heart-failure team.
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.
What the meta-analysis did
The review searched five databases up to September 2025 for randomised trials in adults with heart failure who were already on guideline-directed therapy. The interventions were intravenous NAD+ or oral NR, each compared with placebo. The main outcomes were hospital admission for heart failure, death from any cause and change in left ventricular ejection fraction (LVEF, the share of blood the main pumping chamber pushes out with each beat). Four randomised trials with 387 patients met the criteria. The protocol is registered on PROSPERO (CRD420251251462), and the authors declare no competing interests.
Heart-failure outcomes: Limited (four small trials, no significant benefit)
Hospital admission for heart failure was not significantly reduced (3 trials, 268 patients; risk ratio 0.63, 95% CI 0.36 to 1.09). Neither was death from any cause (2 trials, 238 patients; risk ratio 0.51, 95% CI 0.09 to 2.86). LVEF did not differ significantly at one month (2 trials, 238 patients; mean difference 2.10 percentage points, 95% CI -0.18 to 4.38), at three months (2 trials, 87 patients; -0.48, 95% CI -4.74 to 3.78) or at the last follow-up (3 trials, 267 patients; 1.54, 95% CI -0.69 to 3.77).
Heart size and strain measures (global longitudinal strain, left atrial diameter, left ventricular end-diastolic diameter and volume) showed no significant differences. NT-proBNP, a blood marker that rises when the heart is under strain, did not differ significantly either (2 trials, 238 patients; mean difference -382.76 pg/mL, 95% CI -1,091.62 to 326.11). The authors conclude that NAD+ and NR did not significantly improve cardiac function, biomarkers or clinical outcomes, although numerical trends favoured treatment. Wide confidence intervals with few patients mean a modest benefit or harm cannot be ruled out either way.
Safety: a small rise in creatinine
Serum creatinine rose significantly with NAD+ (2 trials, 209 patients; mean difference 7.46 µmol/L, 95% CI 2.21 to 12.71), which is roughly 0.08 mg/dL. Alanine aminotransferase (ALT), a liver blood marker, did not differ significantly. The authors describe the interventions as generally well tolerated in the short term, but say the creatinine increase warrants further evaluation. Kidney function matters in heart failure because many heart-failure medicines affect it, so this is a reason for caution, not a finding to dismiss.
The randomised trials cited in the paper
The abstract does not name the four trials. The reference list cites four randomised heart-failure trials of NAD+ or NR: Yu and colleagues, Pei and colleagues, Wang and colleagues, and a Meng preprint. Three of those reports are from single hospitals in China and used intravenous NAD+ for about a week. The sample sizes in the reports are 180, 60, 60 and 30, which sum to 330, not the 387 in the review, and the Pei paper and the Meng preprint share Chinese registration ChiCTR2300074326:
- Yu and colleagues (2026): 180 adults with heart failure caused by ischaemic cardiomyopathy and an LVEF of 45% or less were given 10 mg of intravenous NAD+ or placebo once daily for 7 days in a single centre. LVEF at one month was higher with NAD+ (45.44% v 42.44%, p = 0.024). A lower rate of major adverse cardiac and cerebrovascular events at six months (14.6% v 24.7%) did not reach significance, and the authors say the trial was not powered for clinical events. It was supported in part by a research grant and study drug supply from Kaifeng Knature Pharmaceutical Co.
- Pei and colleagues (2024): 60 hospital patients older than 60 with heart failure received 50 mg of intravenous NAD+ or saline for 7 days, alongside usual heart-failure drugs. Improvements in NT-proBNP and LVEF were better with NAD+ but not statistically significant. The NAD+ was a Kaifeng Knature product with Chinese national drug approval number H41024721. The authors report a Knature grant and thank the company for the powder, and they state that Hefei Knature was not involved in the study. The trial was registered retrospectively (ChiCTR2300074326).
- Meng and colleagues (2023, posted as a preprint): a single-centre study at Beijing Hospital. Sixty people with heart failure received 50 mg a day of Coenzyme I for injection, or saline, for 7 to 10 days, with usual heart-failure treatment. LVEF improved significantly in both groups among the 55 who completed the study. The preprint shares five authors with the Pei paper and Chinese registration ChiCTR2300074326. The authors thank Hefei Kangnuo Biological Pharmaceutical Co. Ltd and say the data are available from that company. They declare no competing interests.
- Wang and colleagues (2022): the oral NR trial among these reports. 30 people with stable heart failure with reduced ejection fraction were randomised 2:1 to NR or placebo for 12 weeks, reaching 1,000 mg twice daily. It met its primary safety endpoint, NR roughly doubled whole-blood NAD+, and there were no significant on-trial changes in the prespecified laboratory or clinical measures. The NR and placebo were supplied as Niagen capsules by ChromaDex. The authors say the company had no role in funding, design, conduct, analysis or writing.
Some of the single trials report positive findings, but the pooled results for admissions for heart failure, deaths, pumping function and NT-proBNP are not significant. Three of the four reports used intravenous NAD+ for about a week (Yu and Pei name Chinese approval number H41024721; Meng and colleagues call it Coenzyme I for injection), in people already taking heart-failure drugs. They say nothing about wellness-clinic drips, NMN capsules or long-term use by healthy people.
Muscle ageing: a second review the same week
A structured review in GeroScience, published online on 16 November 2026, looked at dietary nucleotides and NAD+ precursors in age-related sarcopenia (loss of muscle strength and mass). It included 65 publications. The authors say evidence on NAD+ precursors is considerably more extensive than for conventional nucleotides, but the clinical findings are heterogeneous. They conclude that current evidence does not justify treating nucleotide mixtures, nucleoproteins, NMN and NR as equivalent, or recommending their routine use for sarcopenia.
Our view
- The first pooled look at NAD+ and NR in heart failure is a null result: no significant effect on admissions for heart failure, deaths, pumping function or NT-proBNP across four small trials.
- Treat any claim that NAD+, NMN or NR supports heart health in people with heart failure as unproven. The trials are small, short and mostly intravenous, and no NMN trial in heart failure was included.
- The creatinine rise is small, and it was statistically significant in the pooled data from two trials. If you have heart or kidney disease, ask your heart-failure team or pharmacist before taking any NAD+ product.
- Larger trials with clinical endpoints are needed, as both the meta-analysis authors and the largest trial's authors say.
UK rules
The NHS lists medicines such as diuretics, medicines that widen the blood vessels and beta blockers among the treatments for heart failure, and advises taking medicine as your doctor has prescribed. A food supplement is not a substitute for any of them. Tell your GP, heart-failure nurse or pharmacist before adding an NAD+, NR or NMN product, and report suspected side effects through the MHRA's Yellow Card scheme.
FAQ
Does NAD+ help heart failure?
Not on current evidence. A 2026 meta-analysis of four randomised trials with 387 patients found no significant reduction in hospital admissions for heart failure or deaths and no significant improvement in pumping function or NT-proBNP with intravenous NAD+ or oral NR added to standard heart-failure medicines.
Is nicotinamide riboside safe for people with heart failure?
The one oral NR trial in heart failure, with 30 people over 12 weeks, met its safety endpoint at up to 1,000 mg twice daily. That is too small and short to settle long-term safety, and the pooled NAD+ comparison found a small rise in serum creatinine (2 trials, 209 patients). Ask your heart-failure team first.
Were NMN or NAD+ drips studied?
No NMN trial in heart failure was included. The intravenous trials used 10 mg or 50 mg of NAD+ a day for about a week in hospital patients, so they do not describe wellness-clinic drips.
Do NAD+ precursors help muscle loss with age?
A November 2026 review in GeroScience found the clinical results for NAD+ precursors heterogeneous and concluded that current evidence does not justify recommending NMN or NR routinely for sarcopenia.
Sources
These are the documents this page relies on.
- Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. Impact of exogenous nicotinamide adenine dinucleotide and its precursors supplementation in adults with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2026;82(12):295European Journal of Clinical Pharmacology (PubMed 43040090)
- Yu X, Xu J, Cao J, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2026;26(1):97-106American Journal of Cardiovascular Drugs (PubMed 40954388)
- Pei Z, Dong M, Meng X, Yao W, Guo Y, Wang F. Effects of nicotinamide adenine dinucleotide on older patients with heart failure. Rev Cardiovasc Med. 2024;25(8):297Reviews in Cardiovascular Medicine (PubMed 39228487)
- Wang DD, Airhart SE, Zhou B, et al. Safety and tolerability of nicotinamide riboside in heart failure with reduced ejection fraction. JACC Basic Transl Sci. 2022;7(12):1183-1196JACC: Basic to Translational Science (PubMed 36644285)
- Meng X, Li Y, Weng S, et al. Efficacy of nicotinamide adenine dinucleotide in heart failure patients: a randomized, double-blind, placebo-control clinical trial. Preprint, version 1, December 2023Research Square (preprint)
- Gdańska A, Karaś R, Binduga UE, Szychowski KA. Dietary nucleotides and NAD+ precursors in age-related sarcopenia. Geroscience. Published online 16 November 2026GeroScience (PubMed 43040062)
- Heart failure: treatmentNHS
- Yellow Card: report a side effectMedicines and Healthcare products Regulatory Agency